Advertisement
UK markets open in 25 minutes
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,170.78
    +341.85 (+2.03%)
     
  • CRUDE OIL

    83.50
    +0.14 (+0.17%)
     
  • GOLD FUTURES

    2,340.20
    -1.90 (-0.08%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • Bitcoin GBP

    53,517.36
    +68.53 (+0.13%)
     
  • CMC Crypto 200

    1,415.54
    -8.56 (-0.60%)
     
  • NASDAQ Composite

    15,696.64
    +245.33 (+1.59%)
     
  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     

Shire plc : Total voting rights

Total Voting Rights

October 2, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"), in accordance with 5.6.1R of the Financial Conduct Authority`s (the "FCA") Disclosure Guidance and Transparency Rules, notifies the market of the following:

As at September 30, 2017, the Company`s issued ordinary share capital comprised 908,509,840 ordinary shares of 5 pence each with voting rights and a further 7,357,283 ordinary shares held in treasury.

Therefore, the total number of voting rights in the Company is 908,509,840. This is the figure which should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA`s Disclosure Guidance and Transparency Rules.

ADVERTISEMENT

Sarah Rixon
Company Secretarial Assistant

For further information please contact:

Investor Relations

Ian Karp

ikarp@shire.com

+1 781 482 9018

Robert Coates

rcoates@shire.com

+44 1256 894874

Media

Lisa Adler

lisa.adler@shire.com

+1 617 588 8607

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

www.shire.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Shire plc via GlobeNewswire

HUG#2138711